| Name | Title | Contact Details |
|---|
The Permanente Medical Group was established in 1948 with seven original partners. Today, we are an integral part of Kaiser Permanente with the stability of more than 50 years serving the communities of Northern California. As the quality leader in
Thoratec Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Intelect Medical is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Blackrock Neurotech builds implantable brain technology that changes lives. Our pioneering neuroscience tools push the boundaries of research and empower innovation across more than 500+ global institutional partners, restoring function in patients suffering from neurological disease (ALS, Alzheimer`s, Parkinson`s), dysfunction (epilepsy, pain, brain trauma), and paralysis disorders.
ValenTx was founded with the goal of treating some of the most pervasive health problems of our time: obesity and obesity-related metabolic disorders such as type-2 diabetes and hypertension. Our approach is to create a non-surgical, endoluminal bypass device that builds on the success of established medical interventions, resulting in a highly effective and least-invasive therapy. Current treatments for these diseases include surgery, pharmacology, and medically supervised lifestyle management. The risks, costs, and in some cases poor efficacy of these treatments have hampered their broad adoption by patients, physicians, and payers alike. A truly unmet clinical need exists for a therapy that can deliver the efficacy obtained through surgery, but without the risks and costs associated with surgical intervention. The ValenTx endoluminal bypass therapy mimics the attributes of a Roux-en-Y gastric bypass and is implanted through a non-surgical, endoscopic procedure. This procedure does not require gastric stapling or permanent changes to the patient`s anatomy. The device is removable, replaceable and designed so that the physician could change the therapeutic profile, thereby optimizing the treatment towards the individual patient`s needs. ValenTx has developed a strong intellectual property portfolio, which lies at the foundation of this therapy. The company has successfully conducted a series of clinical studies demonstrating the viability, safety, and efficacy of the therapy.